Suppr超能文献

Ly6/uPAR 相关蛋白 C4.4A 作为肺腺癌实体生长模式和不良预后的标志物。

Ly6/uPAR-related protein C4.4A as a marker of solid growth pattern and poor prognosis in lung adenocarcinoma.

机构信息

The Finsen Laboratory, Rigshospitalet, Copenhagen Biocenter, Copenhagen, Denmark.

出版信息

J Thorac Oncol. 2013 Feb;8(2):152-60. doi: 10.1097/JTO.0b013e318279d503.

Abstract

INTRODUCTION

We have recently shown that the protein C4.4A is induced in early precursor lesions of pulmonary adenocarcinomas and squamous cell carcinomas. In the present study, we aimed at analyzing the impact of C4.4A on the survival of non-small cell lung cancer patients and determining whether its unexpected expression in adenocarcinomas could be attributed to a specific growth type (lepidic, acinar, papillary, micropapillary, solid).

METHODS

Sections from the center and periphery of the primary tumor, as well as N2-positive lymph node metastases, were stained by immunohistochemistry for C4.4A and scored semi-quantitatively for intensity and frequency of positive tumor cells.

RESULTS

C4.4A score (intensity × frequency) in the tumor center was a highly significant prognostic factor in adenocarcinomas (n = 88), both in univariate (p = 0.004; hazard ratio [95% confidence interval] = 1.44 [1.12-1.85]) and multivariate statistical analysis (p = 0.0005; hazard ratio = 1.65 [1.24-2.19]), demonstrating decreasing survival with increasing score. In contrast, C4.4A did not provide prognostic information in squamous cell carcinomas (n = 104). Pathological stage was significant in both groups. In the adenocarcinomas, C4.4A expression was clearly associated with, but a stronger prognostic factor than, solid growth.

CONCLUSIONS

The present results substantiate the potential value of C4.4A as a prognostic marker in pulmonary adenocarcinomas seen earlier in a smaller, independent patient cohort. Importantly, we also show that C4.4A is a surrogate marker for adenocarcinoma solid growth. Recent data suggest that C4.4A is negatively regulated by the tumor suppressor liver kinase B1, which is inactivated in some adenocarcinomas, providing a possible link to the impact of C4.4A on the survival of these patients.

摘要

简介

我们最近发现,蛋白 C4.4A 在肺腺癌和鳞状细胞癌的早期前体病变中被诱导表达。在本研究中,我们旨在分析 C4.4A 对非小细胞肺癌患者生存的影响,并确定其在腺癌中的意外表达是否归因于特定的生长类型(贴壁型、腺泡型、乳头型、微乳头型、实体型)。

方法

用免疫组织化学法对原发肿瘤的中心和周围部位以及 N2 阳性淋巴结转移灶进行 C4.4A 染色,并对肿瘤细胞的阳性强度和频率进行半定量评分。

结果

腺癌(n = 88)中肿瘤中心的 C4.4A 评分(强度×频率)是一个非常显著的预后因素,无论是在单因素(p = 0.004;危险比[95%置信区间] = 1.44[1.12-1.85])还是多因素统计分析(p = 0.0005;危险比 = 1.65[1.24-2.19])中,评分越高,生存率越低。相比之下,C4.4A 并未为鳞状细胞癌(n = 104)提供预后信息。在两组中,病理分期都有意义。在腺癌中,C4.4A 的表达与实体生长密切相关,但作为预后因素比实体生长更强。

结论

本研究结果进一步证实了 C4.4A 作为肺腺癌早期较小、独立患者队列的潜在预后标志物的价值。重要的是,我们还表明 C4.4A 是腺癌实体生长的替代标志物。最近的数据表明,C4.4A 受肿瘤抑制因子肝激酶 B1 的负调控,而在一些腺癌中肝激酶 B1 失活,这为 C4.4A 对这些患者生存的影响提供了一个可能的联系。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验